Abstract
AbstractIn late 2023, a lineage of SARS-CoV-2 emerged and was named the BA.2.86 variant. BA.2.86 is phylogenetically distinct from other Omicron sublineages identified so far, displaying an accumulation of over 30 amino acid mutations in its spike protein. Here, we performed multiscale investigations to reveal the virological characteristics of the BA.2.86 variant. Our epidemic dynamics modeling suggested that the relative reproduction number of BA.2.86 is significantly higher than that of EG.5.1. Experimental studies showed that four clinically-available antivirals were effective against BA.2.86. Although the fusogenicity of BA.2.86 spike is similar to that of the parental BA.2 spike, the intrinsic pathogenicity of BA.2.86 in hamsters was significantly lower than that of BA.2. Since the growth kinetics of BA.2.86 is significantly lower than that of BA.2 in bothin vitrocell cultures andin vivo, it is suggested that the attenuated pathogenicity of BA.2.86 is due to its decreased replication capacity.
Publisher
Cold Spring Harbor Laboratory
Reference51 articles.
1. GitHub (2023). “2nd-Generation BA.2 Saltation Lineage, >30 spike mutations (3 seq, 2 countries, Aug 14) (August 14, 2023)”. https://github.com/cov-lineages/pango-designation/issues/2183#issue-18 49123156.
2. Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant
3. WHO (2023). “Tracking SARS-CoV-2 variants (October 26, 2023)” https://www.who.int/en/activities/tracking-SARS-CoV-2-variants.
4. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86
5. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike